格隆汇12月23日丨科济药业-B(02171.HK)公告，12月23日耗资486.1万港元回购32万股。 ...

FF305 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年12月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發 ...

Core Insights - The chairman of Kogei Pharmaceuticals, Li Zonghai, stated that universal CAR-T products are expected to reduce treatment costs to around 10,000 yuan per injection, significantly improving accessibility for patients [1][2][7]. Industry Overview - Currently, there are 7 CAR-T products approved in the U.S. and 8 in China, with the U.S. having a stronger commercial environment and payment capacity [3]. - China is improving its payment capabilities and policy environment, which may allow it to catch up with the U.S. in CAR-T product development [3]. Product Development - Kogei Pharmaceuticals has submitted the world's first NDA for a CAR-T product targeting solid tumors, expected to be approved by mid-next year [4]. - The company is focusing on both autologous and universal CAR-T products, with a shift towards universal CAR-T as a core growth engine due to its broader market potential and lower production costs [6][14]. Cost Reduction Strategy - The universal CAR-T product is projected to lower costs significantly, potentially to one-fiftieth of current prices, enhancing production efficiency and reducing failure rates [7]. - The company aims to have the first universal CAR-T product on the market by 2030, with a focus on overcoming challenges related to immune rejection [8][10]. Commercialization Efforts - Kogei's first commercial product, Saikeze, achieved revenue of 50.96 million yuan in the first half of 2025, marking a 703.8% year-on-year increase [11]. - The company is building its own commercialization team to support the launch of its products, particularly in the gastric cancer market, which has significant unmet clinical needs [12]. Global Expansion Plans - Kogei Pharmaceuticals plans to expand into Asian markets, including Hong Kong, Singapore, and South Korea, while also targeting Western markets where similar products are not available [13]. Future Research and Development - The company will prioritize funding for the development of universal CAR-T products and expanding the indications for its existing products [14].

Core Viewpoint - The CAR-T cell therapy is a revolutionary cancer immunotherapy method, but its high cost (up to millions) limits accessibility for many patients. However, there is potential for significant cost reduction with universal CAR-T products, which could lower the price to around 10,000 yuan per injection, enhancing drug accessibility [2][3]. Group 1: Market and Competitive Landscape - The global CAR-T product landscape shows strong development in the US and China, with 7 and 8 products approved respectively. The US has a stronger commercial environment and payment capacity compared to China, which is improving [8]. - China is synchronized with international standards in blood cancer CAR-T development and has a lead in solid tumor CAR-T products, with no overseas products in critical clinical stages yet [8]. - China is at the forefront of universal CAR-T technology, while it ranks among the top globally in autologous CAR-T development [8]. Group 2: Product Development and Cost Reduction - The first NDA for a solid tumor CAR-T product, CT041, is expected to be approved in the first half of next year [10]. - The company is focusing on developing universal CAR-T products, which are anticipated to have a broader market space and lower production and management costs [12][13]. - The cost of universal CAR-T products could potentially drop to one-fiftieth of the current autologous CAR-T costs, estimated at around 10,000 yuan per injection [14]. Group 3: Future Outlook and Challenges - The first universal CAR-T product is projected to be launched before 2030, with a timeline of approximately four years for clinical trials and regulatory approvals [16][17]. - A significant challenge in developing universal CAR-T products is addressing rejection issues, which many companies face. The company has a unique platform that shows promising early clinical trial data [18]. Group 4: Commercialization Strategy - The company has achieved significant revenue growth with its first commercial product, with a 703.8% increase in revenue year-on-year [20]. - The company is building its own commercialization team, anticipating that its products will meet substantial clinical needs in the domestic market, especially for gastric cancer [22]. - The company plans to expand its market reach to Asia and eventually to Europe and the US, where there are no similar products available [24]. Group 5: Research and Development Focus - Future R&D investments will prioritize expanding indications for CT041 and accelerating the market entry of universal CAR-T products [25]. - The company aims to lower the cost of solid tumor CAR-T products to around 10,000 yuan while achieving efficacy comparable to autologous products, which is crucial for broader accessibility [25].

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新数据显示，12月18日，非执行董事郭华清增持科济药业（02171）1.8万股，每股作价 14.52港元，总金额约为26.14万港元。增持后最新持股数目约为2.25亿股，持股比例为39.01%。 责任编辑：卢昱君 香港联交所最新数据显示，12月18日，非执行董事郭华清增持科济药业（02171）1.8万股，每股作价 14.52港元，总金额约为26.14万港元。增持后最新持股数目约为2.25亿股，持股比例为39.01%。 责任编辑：卢昱君 ...

Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical (02171) by purchasing 18,000 shares at a price of HKD 14.52 per share, totaling approximately HKD 261,400, which reflects confidence in the company's future prospects [1] Group 1 - The total number of shares held by Guo Huaqing after the purchase is approximately 225 million shares [1] - The ownership percentage of Guo Huaqing in Kintor Pharmaceutical is now 39.01% [1]

Group 1 - The core point of the article is that non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical (02171) by acquiring 18,000 shares at a price of HKD 14.52 per share, totaling approximately HKD 261,400 [1] - After the purchase, Guo's total shareholding in Kintor Pharmaceutical reached approximately 225 million shares, representing a 39.01% ownership stake [1]

Group 1: Market Overview - The pharmaceutical and biotechnology index decreased by 0.14% from December 15 to December 19, outperforming the ChiNext and CSI 300 indices [1][23] - The total trading volume in the pharmaceutical sector was 389.82 billion yuan, accounting for 4.49% of the total trading volume in the Shanghai and Shenzhen markets, which is below the average of 7.12% since 2013 [1][38] - The pharmaceutical sector ranked 18th in terms of weekly performance among all industries during the same period [1][25] Group 2: Sector Analysis - The recent lack of significant industrial catalysts has led to a muted beta effect in the sector, but many stocks have entered a value range, indicating potential for a rebound [2][59] - The "reward economy" theme has positively influenced certain pharmaceutical companies, particularly those linked to Ant Group and related retail channels [2][59] - Strong performance was noted in CXO, small nucleic acids, and certain innovative drugs, driven by specific stock factors such as BD expectations and overseas mapping [2][59] Group 3: In Vivo CAR-T Developments - In vivo CAR-T technology is expected to address the accessibility issues of CAR-T therapies, potentially lowering treatment costs and making it available as a shelf product [4][12] - Major pharmaceutical companies are actively investing in in vivo CAR-T, with business development (BD) transactions exceeding 5 billion USD, indicating its strategic importance [4][16] - Clinical data presented at the 2025 ASH meeting showed promising results for in vivo CAR-T therapies, with high rates of minimal residual disease (MRD) negativity in patients [4][19] Group 4: Future Outlook - The company maintains a positive outlook on innovation, international expansion, and turnaround opportunities in the pharmaceutical sector, focusing on BD 2.0, small nucleic acids, and supply chains as key investment areas [3][22] - The upcoming 2026 potential catalysts include the publication of the commercial insurance innovation drug directory and the commercialization of targeted CAR-T therapies [21][22] - Domestic companies are rapidly advancing in the in vivo CAR-T space, with several candidates in early clinical stages, indicating a growing competitive landscape [22][22]

Core Viewpoint - The company has repurchased a total of 7.627 million shares under its share buyback authorization from October 21, 2025, to December 17, 2025, indicating confidence in its long-term growth and market performance [1] Group 1 - The board believes the current stock price is below its true value and does not reflect the company's business prospects adequately [1] - The share buyback plan has been extended until the conclusion of the next annual general meeting, demonstrating the board's commitment to shareholder interests [1] - The board has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 335,000 shares between November 6, 2025, and December 17, 2025, increasing their total holdings to 218,283,730 shares, representing approximately 38.2% of the total issued shares [1] Group 2 - The board views the increase in shareholding by major shareholders as a sign of confidence in the company's future and growth potential, as well as recognition of its long-term investment value [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171.HK) announced that the Yijie Biotechnology Holdings Limited and its concerted parties have cumulatively purchased 335,000 shares between November 6, 2025, and December 17, 2025, increasing their stake to approximately 38.2% of the total issued shares excluding treasury shares as of the announcement date [1]. Group 1 - Yijie Biotechnology Holdings Limited and its concerted parties are collectively referred to as the "Yijie Concerted Action Group" [1]. - The total number of shares held by the Yijie Concerted Action Group after the purchase is 218,283,730 shares [1]. - The purchase of shares indicates a significant increase in ownership percentage, reflecting confidence in the company [1].